

Review of: "[Review Article] Pitavastatin: A Comprehensive Overview of its Mechanisms, Pharmacokinetics, Pharmacodynamics, and Adverse Effects"

Anil Sukumaran¹

¹ University of Hong Kong

Potential competing interests: No potential competing interests to declare.

Pitavastatin: A Comprehensive Overview of its Mechanisms, Pharmacokinetics, Pharmacodynamics, and Adverse Effects

Overall Impression:

The article provides a comprehensive review of pitavastatin, an HMG-CoA reductase inhibitor used to treat dyslipidemia and hypercholesterolemia. The authors have covered various aspects of pitavastatin, including its chemical structure, pharmacodynamics, pharmacokinetics, lipid-lowering effects, drug interactions, and adverse effects. The article is well-structured and informative.

Language and Integrity:

The language used in the manuscript is generally clear and easy to follow. However, a few grammatical errors and awkward sentence constructions should be addressed. For example:

- In the Introduction, "Pitavastatin is recognized by its chemical term, (+) monocalcium bis-[(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate], and its molecular weight is 880.98[1]." - This sentence reads awkwardly and should be rephrased.
- There are a few typos and punctuation errors scattered throughout (e.g., "augmentation from RCT [57]" in the Conclusions - the reference number should be superscript).
- Some sentences are overly long and convoluted, making them harder to parse (e.g., the 2nd sentence under "Drug Interaction"). Consider breaking them up.

I recommend having the manuscript carefully proofread and copy-edited to polish the language.

Suggestions for Improvement:

1. The abstract could be structured with subheadings (e.g., Background, Methods, Results, Conclusions) to provide a clearer overview.
2. Some sections (e.g., "Drug Interaction", "Other Side Effects") read more like a literature summary than a synthesized

review. The authors should aim to critically analyze and integrate the findings rather than simply listing study results.

What are the key takeaways and implications of the drug interaction and side effect data?

3. The Discussions section could be more comprehensive. Expand on how this review adds to the current understanding of pitavastatin's clinical use and positioning compared to other statins. What are the advantages and limitations? What key questions remain unanswered?

4. Check that the most recent and relevant studies are cited. For example, reference 28 on using pitavastatin as a tracer is from 2015. Are there any newer developments worth mentioning?

5. A brief concluding paragraph summarizing the review's main points and future directions would enhance the manuscript.

I hope the authors find these comments useful for strengthening their manuscript. With some polishing, this review will be a valuable and comprehensive resource on pitavastatin. Please feel free to reach out if you have any other questions.